Updated October 7, 2026. This article is for educational purposes only and is not investment advice. Figures and regulatory milestones are taken from uniQure’s public filings and press releases and can change quickly.
uniQure N.V. (NASDAQ: QURE) is a gene therapy company headquartered in Amsterdam, the Netherlands, with US operations in Lexington, Massachusetts. Some investors search for it as “Qure stock” because of its ticker symbol. The company develops one-time treatments that deliver working genes to patients with serious inherited and neurological diseases.
This guide explains what uniQure does, where its key programs stand in 2026, how the company is funded and the main risks to understand before you research the stock further.
uniQure’s History and Background
uniQure traces its roots to Amsterdam Molecular Therapeutics, a spin-out from academic research in Amsterdam founded in 1998. The company took the uniQure name in 2012 and listed its shares on the Nasdaq in 2014.
uniQure was a gene therapy pioneer: its earlier product, Glybera, was the first gene therapy approved in the European Union in 2012, although it was later withdrawn for commercial reasons. Most of the company’s programs use adeno-associated virus (AAV) vectors, harmless viruses engineered to carry a therapeutic gene into specific tissues such as the liver or the brain.
Hemgenix: The Approved Hemophilia B Therapy
uniQure’s former lead candidate, AMT-061 (etranacogene dezaparvovec), is a gene therapy for adults with hemophilia B, a bleeding disorder caused by a lack of clotting factor IX. uniQure licensed global rights to CSL Behring, and the therapy is now sold by CSL Behring as Hemgenix. It was approved by the US Food and Drug Administration (FDA) in November 2022 and received conditional approval in the European Union in early 2023.
For uniQure, Hemgenix generates royalties and potential milestone payments rather than direct product sales. In 2023, uniQure sold the lowest tier of its Hemgenix royalties to outside investors for an upfront payment of $375 million, which it records as a royalty financing liability. In 2024, it also sold its Lexington manufacturing facility; Hemgenix is now manufactured for CSL Behring by a third party on uniQure’s behalf.
AMT-130: The Huntington’s Disease Program
Today, the stock is driven mainly by AMT-130 (ifezuntirgene inilparvovec), an investigational gene therapy for Huntington’s disease, a fatal inherited neurodegenerative disorder. It is given once, through MRI-guided neurosurgery, and is designed to lower production of the huntingtin protein. The FDA has granted it Breakthrough Therapy, Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations.
Key 2026 milestones, according to the company:
- June 2026: after a meeting with the FDA, uniQure said the agency found three-year data from its Phase I/II study, compared with an external natural-history control group, acceptable as the primary basis for an accelerated approval application.
- September 2, 2026: uniQure submitted a Biologics License Application (BLA) to the FDA requesting accelerated approval and priority review, and filed a marketing application with the UK’s MHRA.
- September 29, 2026: the company reported updated Phase I/II data. These newer results were not part of the original BLA. At the time of writing, uniQure expected the FDA’s decision on whether to accept the BLA for review in the fourth quarter of 2026.
Accelerated approval, if granted, would typically require a confirmatory study. Investors should note that the program relies on a small number of patients and on an external comparison group rather than a placebo-controlled trial, which is a common point of debate among analysts and regulators.
Other Pipeline Programs
uniQure also has earlier-stage gene therapy programs in areas such as refractory temporal lobe epilepsy, Fabry disease and SOD1-related ALS. Early-stage programs carry a high risk of failure and their status changes often, so check the latest investor presentation for current details.
uniQure’s Finances: What to Look At
uniQure is not consistently profitable and funds its research mainly through cash reserves, share offerings, royalty financing and partner payments. The company reported about $622.5 million in cash, cash equivalents and current investment securities at the end of 2025, after raising roughly $404 million through stock offerings during the year, and said it expected this to fund operations into the second half of 2029.
When you review its quarterly reports on the SEC’s EDGAR database, focus on:
- Cash runway and cash burn: how long current cash is expected to last and how quickly it is being spent.
- Dilution: new share offerings raise money but reduce existing shareholders’ ownership.
- Royalty and milestone income: Hemgenix-related income depends on CSL Behring’s sales and on the royalty financing terms.
- Regulatory calendar: FDA acceptance, review timelines and any advisory committee meetings.
uniQure’s Risks and Challenges
- Regulatory risk: the FDA may refuse to file the application, ask for more data or decline accelerated approval. Any of these outcomes could cause a sharp fall in the share price.
- Clinical and safety risk: gene therapies are delivered once and their long-term effects are still being studied. AMT-130 also requires brain surgery, which carries its own risks.
- Commercial risk: gene therapies are among the most expensive medicines in the world. Pricing, reimbursement and the number of treatment centers able to deliver them can limit uptake, as several earlier gene therapy launches have shown.
- Concentration risk: the company’s value depends heavily on a single program.
- Volatility: clinical-stage biotech stocks can rise or fall by large amounts in a single day on trial results or regulatory news.
How Investors Typically Approach a Stock Like QURE
Because of these binary risks, many investors keep any single speculative biotech stock to a small part of their portfolio, or get exposure through a diversified biotech ETF instead of one company. Rely on primary sources, such as company filings, FDA announcements and peer-reviewed data, and treat social media price targets with caution. If you are unsure whether a stock fits your situation, speak with a licensed financial professional.
Frequently Asked Questions
Is “Qure stock” the same as uniQure?
Yes. QURE is the Nasdaq ticker symbol of uniQure N.V.
Does uniQure sell Hemgenix itself?
No. CSL Behring holds the global rights and sells Hemgenix. uniQure receives royalties and milestone payments, part of which it has sold to outside investors.
What is the biggest catalyst for uniQure stock?
The FDA’s handling of the AMT-130 application for Huntington’s disease, starting with whether the agency accepts the BLA for review.
Does uniQure pay a dividend?
No. Like most clinical-stage biotech companies, uniQure reinvests its cash in research and development.
Disclaimer: this article is general information, not a recommendation to buy or sell any security. Investing in individual biotech stocks involves a high risk of loss. Please read our Disclaimer.
